⌕
Allogene Therapeutics · ALLO · Nasdaq
Tenet 65 · Solid
Compare
$0.70−6.48%At closeTenet 65 · Solid
$0.70−0.05 (−6.48%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

Allogene Therapeutics (ALLO) Institutional Ownership

13F filers reported holding 87.8% of Allogene Therapeutics (ALLO) shares as of Sep 30, 2026, across 197 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
87.8%
Sep 30, 2026
13F filers
197
quarter ended Sep 30, 2026
13F value
$487.7M
304.1M shares
Quarter's fund flow
Mild distribution
25 new · 31 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds trimmed or exited than added or entered, mild distribution (25 new · 55 increased · 77 reduced · 31 closed · 9 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 50 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 197 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 50 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 21, 2026Parker Geoffrey M.CHIEF FINANCIAL OFFICERDisposed · Open-market sale36,342$1.34↗
Aug 21, 2026Douglas Earl MartinSVP, General CounselDisposed · Open-market sale29,697$2.12↗
Jul 1, 2026Roberts ZacharyPresident and CEOAcquired · Grant / award134,530Restricted Stock Unit—↗
Jul 1, 2026Roberts ZacharyPresident and CEOAcquired · Grant / award476,190Stock Option (Right to buy)—↗
Jun 18, 2026Barrett Elizabeth A.directorAcquired · Grant / award95,400Restricted Stock Unit—↗
Jun 18, 2026MESSEMER DEBORAH M.directorAcquired · Grant / award95,400Restricted Stock Unit—↗
Jun 18, 2026Mayo StephendirectorAcquired · Grant / award144,400Stock Option (Right to buy)—↗
Jun 18, 2026WITTE OWEN N.directorAcquired · Grant / award95,400Restricted Stock Unit—↗
Jun 18, 2026Humer Franz BdirectorAcquired · Grant / award95,400Restricted Stock Unit—↗
Jun 18, 2026Kazam Joshua AdirectorAcquired · Option exercise47,700—↗
Jun 18, 2026Kazam Joshua AdirectorDisposed · Option exercise47,700Restricted Stock Unit—↗
Jun 18, 2026Kazam Joshua AdirectorAcquired · Grant / award95,400Restricted Stock Unit—↗
Jun 18, 2026SATO VICKI LdirectorAcquired · Grant / award95,400Restricted Stock Unit—↗
Apr 21, 2026Yoshiyama AnnieSVP, FinanceDisposed · Open-market sale9,586$2.31↗
Mar 31, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerDisposed · Open-market sale2,867$2.50↗
Mar 16, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerDisposed · Open-market sale4,835$2.47↗
Mar 16, 2026Chang David DPresident and CEODisposed · Open-market sale47,763$2.47↗
Mar 2, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerDisposed · Open-market sale7,132$2.60↗
Feb 2, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerDisposed · Open-market sale7,549$1.73↗
Feb 2, 2026Beneski Benjamin MachinasSVP, Chief Technical OfficerAcquired · Grant / award373,757Stock Option (Right to buy)—↗

* Holdings as reported for Sep 30, 2026, 50 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Allogene Therapeutics do institutions hold?

13F filers reported holding 87.8% of Allogene Therapeutics' shares as of Sep 30, 2026, across 197 filers.

How many 13F filers hold Allogene Therapeutics?

Allogene Therapeutics was held by 197 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.